Company / R&D Expense
Olema Pharmaceuticals, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$124.5M
FY2024
5-year range
$13.7M / $124.5M
FY2020-FY2024
Trend
+44.6%
vs FY2023
Sector context
#119 of 210
Health Care
What the data says
At $125M, Olema Pharmaceuticals, Inc.'s r&d expense ranks #119 of 210 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $4M in FY2019 to $125M in FY2024.
Based on SEC 10-K filings.
$125M in FY2024 with a 5-year CAGR of +99.7%.
Improved from $82M to $125M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +34.6%
- 5-Year CAGR
- +99.7%
- 10-Year CAGR
- -
Sector benchmark
#119 of 210 in Health CareTop 57% of 210This company $124.5M Sector average $644.1M
▼
-80.7% below sector average
Key checks
Key Insights
- Olema Pharmaceuticals, Inc.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +99.7%, indicating consistent growth.
- In FY2024, r&d expense increased 44.6% year-over-year.
- Ranks #119 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $124.5M | +44.6% |
| FY2023 | $86.1M | +4.7% |
| FY2022 | $82.3M | +61.0% |
| FY2021 | $51.1M | +272.9% |
| FY2020 | $13.7M | +249.6% |
| FY2019 | $3.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026